Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > T2 BioSystems Appoints Ken Toso Vice President, Product Development

Abstract:
T2 Biosystems, Inc., a company developing the first point-of-care medical diagnostic products that enable rapid molecular and immunodiagnostic testing on a single instrument, today announced it has appointed Ken Toso as Vice President, Product Development.

T2 BioSystems Appoints Ken Toso Vice President, Product Development

Cambridge, MA | Posted on January 6th, 2010

This appointment and creation of a new position reflects the Company's progress in developing its technology for commercial utility as it moves from an alpha instrument completed in 2009 to beta instrument development during 2010.

T2 Biosystems is developing the next generation of medical diagnostic products through its proprietary technology, which combines nanotechnology and the miniaturization of proven MR technology. T2 Biosystems' magnetic resonance-based diagnostics are poised to offer improved speed, accuracy and efficiency, as well as portability to a broader range of settings including doctor's offices, homes and hospitals.

Mr. Toso brings to T2 BioSystems more than 25 years of industry experience in medical device technologies, spanning product research, development and manufacturing. His innovative product experiences and launches have spanned multiple clinical areas within the fields of in vitro diagnostics and medical devices, including General Surgery, Gynecology, Urology, Cardiology, Oncology and Blood Glucose Monitoring.

"We are delighted to welcome Ken to our leadership team as his expertise will be invaluable as we advance our technology towards the marketplace," said John McDonough, CEO of T2 Biosystems. "Ken is joining T2 at a critical time of our growth and evolution to a commercial- stage company."

Most recently, Mr. Toso served as Sr. Vice President of Engineering at Grove Instruments and as Vice President of Research and Development for the Oncology division of Boston Scientific where he directed the launch of eight new products in one year's time. Prior to Boston Scientific, Mr. Toso served as VP of R&D for ACMI Circon and had directed the launch of 22 new products within his 3-year tenure. Mr. Toso also served as Vice President of Engineering at Xylum and started his career at US Surgical, where he served in a variety of technical and management roles, directing the launch of more than 35 new products. Mr. Toso earned his Bachelor's degree in Mechanical Engineering from SUNY at Stony Brook and M.B.A. from the University of Bridgeport and holds more than 20 US granted patents.

T2 Biosystems' technology has been validated in multiple published journal articles and has shown to accurately analyze viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets. The Company is developing a pipeline of diagnostic products based on its technology, including devices for hospitals, diagnostic laboratories and medical offices, as well as individual patients.

####

About T2 Biosystems
T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Yates Public Relations
Adriana Jenkins
617-744-1713

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Basque researchers turn light upside down February 23rd, 2018

Stiffness matters February 23rd, 2018

Imaging individual flexible DNA 'building blocks' in 3-D: Berkeley Lab researchers generate first images of 129 DNA structures February 22nd, 2018

'Memtransistor' brings world closer to brain-like computing: Combined memristor and transistor can process information and store memory with one device February 22nd, 2018

Nanomedicine

Stiffness matters February 23rd, 2018

Histology in 3-D: New staining method enables Nano-CT imaging of tissue samples February 22nd, 2018

Imaging individual flexible DNA 'building blocks' in 3-D: Berkeley Lab researchers generate first images of 129 DNA structures February 22nd, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

Announcements

Basque researchers turn light upside down February 23rd, 2018

Stiffness matters February 23rd, 2018

Histology in 3-D: New staining method enables Nano-CT imaging of tissue samples February 22nd, 2018

Developing reliable quantum computers February 22nd, 2018

Appointments/Promotions/New hires/Resignations/Deaths

Ocean Optics Grows Sales Organization with Executive Appointments: Henry Langston promoted, Christine Stannard joins spectral sensing product developer December 23rd, 2017

Emmanuel Sabonnadiere is Letiís New CEO November 28th, 2017

Nanometrics Board of Directors Names Pierre-Yves Lesaicherre President and CEO November 14th, 2017

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanobiotechnology

Stiffness matters February 23rd, 2018

Histology in 3-D: New staining method enables Nano-CT imaging of tissue samples February 22nd, 2018

Imaging individual flexible DNA 'building blocks' in 3-D: Berkeley Lab researchers generate first images of 129 DNA structures February 22nd, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project